NMS-032 - SNP-6: A Novel Multi-Mechanistic Therapy for MASH with Evidence from Preclinical and Phase 2a study

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: NMS-032
• By: HU, Oliver Yoa-pu (R&D Center, Sinew Pharma INC, Taiwan)
• Co-author(s): Prof Oliver Yoa-pu Hu (School of Pharmacy, National Defense Medical Center, Taipei, Taiwan / Taipei Medical University, Taipei, Taiwan)
  Dr. Hsin-Tein Ho (R&D Center, Sinew Pharma INC, Taipei, Taiwan)
  Dr. Chang-Hui Tsao (R&D Center, Sinew Pharma INC, Taipei, Taiwan)
  Dr. Yu-Lueng Shih (Division of Gastroenterology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan)
  Dr. Tien-Yu Huang (Division of Gastroenterology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan)
  Dr. Wen-Hui Fang (Department of Family Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan)
  Dr. Chang-Hsien Liu (Department of Radiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan)
  Dr. Jung-Chun Lin (Division of Gastroenterology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan)
  Dr. Chih-Weim Hsiang (Department of Radiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan)
  Dr. Kai-Min Chu (R&D Center, Sinew Pharma INC, Taipei, Taiwan)
  Dr. Cheng-Huei Hsiong (R&D Center, Sinew Pharma INC, Taipei, Taiwan)
  Guan-Ju Chen (R&D Center, Sinew Pharma INC, Taipei, Taiwan)
  Yung-En Wu (R&D Center, Sinew Pharma INC, Taipei, Taiwan)
  Jia-Yu Hao (R&D Center, Sinew Pharma INC, Taipei, Taiwan)
  Chin-Wen Liang (R&D Center, Sinew Pharma INC, Taipei, Taiwan)
  Jun-Lan Zheng (R&D Center, Sinew Pharma INC, Taipei, Taiwan)
  Fu-Yi Hsieh (R&D Center, Sinew Pharma INC, Taipei, Taiwan)
  
• Abstract:

  Background Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a wide spectrum, ranging from simple fatty liver to metabolic dysfunction-associated steatohepatitis (MASH), hepatic fibrosis, and ultimately progressing to cirrhosis and hepatocellular carcinoma (HCC). With a global prevalence of approximately 25%, MASLD has..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login